• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

ABPI_Incentivising_Antibioics_peter-pryharski-unsplash_landscape
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 4th January 2011

Measuring Value: OHE at ISPOR

Members of the OHE team participated in a number of sessions at ISPOR’s 13th Annual European Congress in November. This post summarizes the contributions of Prof Nancy Devlin, OHE’s Director of Research.   Nancy Devlin   Members of the OHE…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
Prof Nancy Devlin

Members of the OHE team participated in a number of sessions at ISPOR’s 13th Annual European Congress in November. This post summarizes the contributions of Prof Nancy Devlin, OHE’s Director of Research.

 

Prof Nancy Devlin Nancy Devlin

 

Members of the OHE team participated in a number of sessions at ISPOR’s 13th Annual European Congress in November. This post summarizes the contributions of Prof Nancy Devlin, OHE’s Director of Research.

NICE’s cost effectiveness threshold revisited: new evidence on the influence of cost effectiveness and other factors on NICE decisions

This podium presentation reported on research currently being undertaken by a team comprising Nancy Devlin and Phill O’Neill (OHE), Helen Dakin (Oxford University), Nigel Rice (University of York) and David Parkin (NHS South East Coast). The aims of the research are to investigate the influence of cost effectiveness and other factors on NICE decisions and whether NICE’s threshold has changed over time.

The HTAinSite database and additional data from public NICE documents provide the basis for analysing NICE’s decisions over the past decade. Each of decisions is characterised as a ‘yes’ or a ‘no’, i.e., a recommendation for or against use of a health care technology for a specific patient group. Logistic regression determines the extent to which these decisions can be explained by: (1) the clinical and economic evidence regarding that technology, (2) the characteristics of the patient population, disease or treatment, and (3) contextual factors affecting the conduct of technology appraisal.

Initial results suggest that, first, cost effectiveness alone explains most of NICE’s decisions included in the study, correctly classifying 84% of them. Few other variables proved significant: alternative ways of modelling NICE decisions led to very small variations in the model’s performance. The study also suggests that NICE’s threshold has not changed over time and that cancer treatments have been significantly more likely to be recommended.

This research is a work in progress, with current results based on a sub-set of NICE decisions. A paper reporting the results in full will be discussed at the Health Economics Study Group conference at the University of York in January 2011. Analysis continues on a larger data set, with results expected to be reported early in 2011.

The value of a QALY: is there a single threshold or does context matter?

Nancy Devlin took part in a panel discussion on this topic. Her presentation focussed on the topic in relation to NICE decision making, including the criteria other than cost effectiveness that NICE uses in decision making and how NICE says it uses these criteria in relation to its cost effectiveness threshold range. A lack of clarity exists about how multiple criteria are applied and it was noted that evidence on NHS opportunity costs that could inform the selection of the threshold is lacking. Further, attaching higher weight to QALYs gained by some groups can only be achieved, within a fixed budget, by according lower priority to others.

Modern methods of utility measurement

Nancy Devlin of OHE and Paul Krabbe from the University Medical Centre, Groningen, The Netherlands, presented a workshop that discussed a range of new methods for the valuation of health related quality of life.

Prof Devlin’s presentation focussed on new approaches to the Time Trade Off (TTO) method, including Lead Time-TTO, which overcome some of the problems with conventional approaches to TTO.  A new study[1] suggests that the lead time approach works well in capturing preferences of most people, even for poor health states.  At the same time, however, very long lead times appeared to have little advantage and the choice of the lead time for a given health state may affect the TTO values for that state.

The workshop concluded with a preview of new, web-based valuation technologies being developed by the EuroQol Group and currently being tested for use in valuing EQ-5D-5L.  This incorporates discrete choice, visual analogue scale and LT-TTO valuation methods.


[1] N Devlin et al., A comparison of alternative variants of the lead and lag time TTO.  OHE Research Paper forthcoming

  • Health Technology Assessment…
  • NICE

Related News

  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • September 2020

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Read more
  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • August 2020

Are Discount Rates Used in UK Vaccine Economic Evaluations Jeopardising Investment in Immunisation Programmes?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!